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ABSTRACT 
Magnetic Resonance-guided focused Ultrasound Surgery (MRgFUS) is gaining popularity as an alternative to 
medical and surgical interventions in the management of symptomatic uterine fibroids. Studies have shown that it is an 
effective non-invasive treatment with minimal associated risks as compared to myomectomy and hysterectomy. 
MRgFUS can be offered to a majority of patients suffering from symptomatic uterine fibroids. It has been suggested that 
the use of broader inclusion criteria as well as the mitigation techniques makes it possible to offer MRgFUS to a much 
larger subset of patients than previously believed. This paper will describe how MRgFUS treatment for uterine fibroids 
is performed at the University of Malaya Medical Centre, Kuala Lumpur, Malaysia. © 2009 Biomedical Imaging and 
Intervention Journal. All rights reserved. 
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INTRODUCTION 
Fibroids are benign growths in the uterus, which are 
symptomatic in up to 25 percent of women of 
childbearing age [1]. Symptoms can include heavy and 
prolonged menstrual bleeding, severe pain, bloating and 
constipation or urinary complaints. The most common 
treatment is hysterectomy, a highly invasive surgical 
procedure to remove the uterus, which is associated with 
the usual surgical risks and complications, requires a 
three- to four-day hospital stay and results in patient 
recovery time of six weeks or more [2,3]. All other 
techniques including uterine artery embolisation [4], 
involve some level of incision, hospitalization and 
recovery time. For example, myomectomy requires a 
hospital stay of several days and recovery time of two to 
four weeks [5]. A number of noninvasive alternatives to 
hysterectomy have become available as treatments for 
uterine fibroids [5-9].  
MRgFUS is so disruptive that it will very likely 
overturn the other dominant current “technologies” e.g. 
surgery [10]. Clinical studies demonstrate that MRgFUS 
is a safe and effective treatment for symptomatic uterine 
fibroids [11-13]. Several studies have shown that 
MRgFUS significantly improves clinical symptoms in 
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70% to 80% of women with uterine myomas [13-16]. 
Studies have also demonstrated a correlation between the 
treated volume of the myomas, improvement in 
symptoms, and lesion shrinkage [12]. The results 
demonstrate that successful and durable treatment of 
uterine fibroids with MRgFUS necessitates selecting 
those patients for whom higher non-perfused volumes 
can be attained using the MRgFUS system. 
In contrast to other invasive treatments for uterine 
fibroids, the relatively non-invasive MRgFUS can be 
performed as an outpatient procedure and requires no 
general anaesthesia. The ExAblate 2000 (InSightec Ltd., 
Haifa, Israel) is the first device to combine magnetic 
resonance imaging (MRI) with high-intensity focused 
ultrasound to destroy tumours non-invasively. In contrast 
to other options, the non-invasiveness of the MRgFUS 
technique is associated with minimal risks and 
complications, requires no overnight hospital stay and 
allows most patients to return to work and their normal 
activities in one to two days. 
Safety data from these studies consistently show that 
there are few serious FDA-reportable adverse events 
related to MRgFUS. The only device-related adverse 
events reported especially early on were skin burns 
(secondary to poor coupling from hair and scars on the 
skin) and nerve damage following MRgFUS, which 
resolved within a year [15]. Damage to adjacent organs, 
such as bowel perforation, is also possible during 
treatment but rare [17]. To date, no immediate 
emergency surgical interventions, unexpected short-term 
adverse events or long-term complications have been 
observed after MRgFUS.  
Based on the prospective registry of all known 
pregnancies occurring after MrgFUS, and maintained by 
the device manufacturer and reported to the FDA, 54 
pregnancies in 51 women have occurred. The mean time 
to conception was 8 months after treatment. Live births 
occurred in 41% of pregnancies. There was a 28% 
spontaneous abortion rate, an 11% rate elective 
pregnancy termination rate and 20% ongoing 
pregnancies beyond 20 gestational weeks. The mean 
birth weight was 3.3 kg, and the vaginal delivery rate 
was 64%. [18]  
It also has been suggested that for the NHS in the 
UK, a treatment strategy for symptomatic uterine 
fibroids starting with MRgFUS is likely to be cost-
effective [21]. It also remains cost-effective under 
alternative assumptions regarding current practice, health 
utility estimates before and after treatment, and the 
effectiveness of alternative treatments (complication 
rates, recurrence rates and procedural death rates). 
Currently, MRgFUS has been used for breast 
tumours, painful bony metastases, and liver tumours. For 
the brain, it has been used for the ablation of 
glioblastomas and for functional neurosurgery. Future 
applications for prostate cancer and acute stroke 
treatment are being explored. 
All MRgFUS procedures were performed using the 
ExAblate 2000 (InSightec, Haifa, Israel), which is fully 
integrated with a 1.5 Tesla MR scanner (GE Medical 
Systems, Milwaukee, WI). ExAblate uses a ‘sonication’ 
process wherein focused ultrasound (FUS) destroys 
tissues by concentrating a high-energy beam on a 
specific point and raising its temperature to 60°-85°C. 
Multiple sonications (focal delivery of energy) are 
required to ablate a specific tissue. The MRI system 
provides critical data such as high-resolution 3D imaging 
of the location of the tumour and internal organs as well 
as real-time temperature feedback that indicates the 
degree of tissue heating and coagulation. Thus, this 
integration of FUS with MRI provides a “closed-loop 
therapy and feedback system” that enables the physician 
to adjust treatment parameters and control the treatment, 
helping to ensure a high level of safety and efficacy. This 
is currently not commercially possible on the ultrasound- 
based focused ultrasound systems.  
SCREENING MRI 
If the patient is clinically eligible and interested in 
MRgFUS, she is referred for a screening MRI scan. 
Screening is performed in the prone position to flatten 
the abdomen (on a 1 cm gel pad similar to that used for 
treatment) and to allow the pelvic structures to fall into 
the position they would be in during a potential treatment. 
Imaging consists of several sequences. To identify 
anatomical structures within the pelvis, T2-weighted fast 
spin echo images in axial, sagittal and coronal 
orientations are acquired. To evaluate the presence of 
hemorrhagic or fatty tissues, T1-weighted fast spoiled 
gradient echo (FSPGR) images are acquired in the 
sagittal orientation followed by T1-weighted fat 
suppressed FSPGR images post gadolinium injection in 
order to evaluate the hemodynamic characteristics of the 
fibroids and to assess their potential viability.  
PATIENT SELECTION 
The first, and probably, the most important inclusion 
criterion for selecting MRgFUS as a treatment is the 
existence of uterine fibroid(s) and the relevance of the 
fibroid(s) to the patient’s symptoms. The location and 
size of the fibroids must correlate with the patient’s 
symptoms. However, if a patient’s symptoms do not 
correlate with the size and location of the leiomyomas, 
MRgFUS may not be the appropriate treatment, for 
example, subserosal leiomyomas associated with uterine 
bleeding instead of compression symptoms to adjacent 
organs i.e. bladder and intestines [20]  
The exclusion criteria are as listed in Table 1 [21]  
As bone absorbs ultrasound waves more readily than 
soft tissue, low energies are sufficient to heat a bone 
surface to high temperatures. Consequently, nerves lying 
adjacent to a heated bone surface may be heated resulting 
in pain and, in extreme cases, even result in nerve 
damage [15]. It is now recommended that sonications are 
performed at least 4 cm from bony structures to 
minimize the amount of heating of the bone [14] 
(Figure 1), which can in turn heat the fat surrounding the 
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nerves and lead to stimulation or potentially damage of 
the nerve. Such stimulation of the adjacent sacral nerves 
may result in incomplete treatment with reduced efficacy 
of the procedure if the pain is severe. Therefore, fibroids 
lying close to the lumbosacral plexus or to any bone 
surface require special care in MRgFUS treatment. 
Several mitigation techniques such as tilting the beam 
path to avoid bone, increasing the frequency of the 
ultrasound beam, rectal filling to push the fibroid away 
from the bone [15] (Figure 2) or partial treatment to 
change the subsequent orientation/location of fibroid are 
available.  
Patients are deemed technically suitable for 
MRgFUS if their fibroids mass seems accessible by the 
system (Figure 3) and is not deemed too large in volume. 
A significant proportion of the fibroids mass should be 
no more than 12 cm depth away from the skin line 
(which is the maximum depth of penetration of the 
sound). Fibroids with more than 50% of their volume 
beyond the maximum focus are generally excluded 
unless mitigation techniques are used, for example using 
a thinner acoustic coupling gel pad (reducing the 
distance between the patient and the transducer) or filling 
the rectum with ultrasound gel to push the uterus and the 
fibroids towards the anterior.  
Patients with more than six uterine fibroids of more 
than 4 cm in size each should also possibly be excluded. 
This is generally associated with the fibroids being close 
to the sacrum or hidden behind the bowel and, thus, will 
be inaccessible. Pre-treatment of large fibroids with a 
gonadotropin-releasing hormone (GnRH) agonist helps 
to reduce fibroid volume and increase fibroid tissue 
susceptibility to the treatment, which may improve 
MRgFUS outcomes [22].  
Presence of longitudinal scars in the beam path, 
including those that could not be seen on the MR images 
are also reasons for exclusion. Scar tissue may absorb the 
ultrasound energy and cause pain or result in a skin burn. 
The St Mary’s group has developed an ingenious method 
of highlighting transverse scars [21] where the scar is 
painted with a solution of nail varnish and paramagnetic 
iron oxide particles. This provides an obvious artefact 
along the line of the scar, which can easily be avoided by 
appropriate positioning and angling of the ultrasound 
beam. 
Other exclusion criteria include grossly calcified 
fibroids i.e. the pseudo capsule of the fibroid becomes 
heavily calcified where the ultrasound energy is 
disrupted by the capsular calcifications and cannot pass 
into the body of the fibroid mass. Non-enhancing 
fibroids, which are essentially non-viable, are also 
excluded. They may, however, be treated if they cause 
symptoms such as mass effect (Figure 4). Pedunculated 
fibroids, when attached by a small stalk, are another 
contraindication to MRgFUS as they may detach into the 
abdominal cavity, thus requiring further surgical 
interventions. Patients with other pelvic pathologies 
(such as adenomyosis) should not be treated with 
MRgFUS.  
Table 1  Patient exclusion criteria. 
1.   Hemoglobin <10 mg/dL 
2.   Patient has hemolytic anemia 
3.   Patient has unstable cardiac status including: 
  •  Unstable angina pectoris on medication 
  •  Documented myocardial infarction within six months of protocol entry 
  •  Congestive heart failure requiring medication (other than diuretic) 
  •  Currently taking anti-arrhythmic drugs 
  •  Severe hypertension (diastolic BP > 100 on medication) 
  •  Presence of cardiac pacemaker 
4.   Patient has severe cerebrovascular disease (multiple CVA or CVA within six months) 
5.   Patient is on anti-coagulation therapy or has an underlying bleeding disorder 
6.   Evidence of uterine pathology other than leiomyoma 
7.   Patient has an active pelvic infection 
8.   Patient has an undiagnosed pelvic mass outside the uterus. 
9.   Patient's weight >110 kg 
10.   Patient with extensive longitudinal abdominal scarring in an area of the abdomen directly 
anterior to the treatment area. 
11.   Patient with standard contra-indications for MR imaging such as non-MRI compatible 
implanted metallic devices. 
12.   Individuals who are not able or willing to tolerate the required prolonged stationary prone 
position during treatment (approximately 3 h.) 
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Figure 1  Sagittal T2-WI shows a “black” fibroid which is very close to the LS spine (blue arrows) and cannot be 
treated safely unless the bladder is drained or other mitigation techniques performed. 
 
 
 
 
 
   
(a) (b) 
Figure 2  Sagittal T2-WI of the pelvis. Use of rectal filling (arrows) to displace the uterus away from the sacrum. 
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(a) (b) 
Figure 3  (a) Sagittal T2-WI shows no acoustic window (blue triangle represents the FUS beam path) secondary to 
bowel (asterisks) lying anterior to fibroid (may be overcome by filling the bladder and/or rectum) while 
(b) axial T2-WI shows a good acoustic window. 
 
 
 
 
 
 
*
*
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*
 
(a) (b) 
Figure 4  (a) Sagittal T2-WI shows multiple dark fibroids which on the (b) post contrast T1-WI shows some of the 
fibroids to be non-enhancing (*) and therefore need not be treated. 
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As air bubbles or hard particles may be present in 
the bowel and may reflect or absorb the ultrasonic energy, 
patients with bowel that cannot be potentially shifted 
from the beam path (by bladder or rectal filling) or beam 
angulation are also excluded from treatment.  
What about adenomyosis? Symptoms of 
adenomyosis are very similar to those of fibroid [23] and 
both can occur in the same patient. A junctional zone 
width of more than 12 mm was defined as adenomyosis 
[24]. It is not uncommon to have patients referred for 
screening as fibroids but subsequently found to have 
adenomyosis (35% to 55%) after MR imaging [25].  
The MRgFUS procedure can ablate adenomyosis 
tissue sufficiently and can improve symptoms 
significantly during a period of 3 to 6 months post-
treatment [26] especially those with low-signal intensity 
adenomyosis on T2-weighted MR images. They went on 
to classify the architecture of the non-perfused lesions on 
contrast-enhanced T1-weighted MR images immediately 
after MRgFUS into 3 types: lesions with round margins 
(type R) (Figure 5), serrated margins (type S) (Figure 6), 
and honeycomb structures with numerous small, non-
perfused holes (type H). There is still no long-term 
evidence currently available in print to demonstrate that 
treatment of adenomyosis results in clinical benefit.  
PATIENT PREPARATION  
The patient’s abdomen is shaved and cleaned to 
remove any hair and also checked for the presence of any 
moles or scars as these may result in skin burns. A 
urinary catheter is inserted to control uterine movement 
during the three-hour treatment. An IV line is necessary 
for the administration of sedation. The patient lays prone 
over a water bath in which the transducer is immersed. 
The patient’s abdomen is acoustically coupled with the 
transducer via the water bath using a special gel pad. The 
patient's legs may be wrapped with compression 
stockings to reduce the risk of deep vein thrombosis but 
the authors do not practice this. Prior to starting the 
treatment, 100 mg Diclofenac sodium is given as a 
suppository. The patient is then positioned prone on the 
ExAblate treatment table with her abdomen over the 
water bath containing the ultrasound transducer. Patient’s 
blood pressure, heart rate, oxygenation, and comfort 
level are monitored throughout the treatment. The 
position of the patient over the transducer is determined 
from a 3plane localizer and T2-weighted imaging. This is 
to maximise the window available for the treatment of 
fibroids (images of poor positioning and images of 
baseline and MRI showing good positioning). 
Midazolam 2 mg is given via IV once the patient has 
been properly positioned on the FUS table. Pethidine 
50 mg and Maxolon 20 mg are administered just prior to 
performing the sonications.  
It is essential that the patient is comfortable in the 
position for the procedure. The authors ensure there is 
support for the head and arms, and provide headphones 
and ear plugs. Communication is provided through the 
2 way-intercom and an emergency button. Analgesia is 
topped up regularly and the bladder, if filled to provide 
an acoustic window, is drained by 30-40 ml every 
30 minutes to minimise the displacement of the uterus 
due to continued filling via the kidneys. The authors use 
updated MRI images to visualise the location of the 
fibroid in relation to the intended target fibroids (i.e. the 
center of the transducer) and make appropriate 
adjustments to the patient's position. The MRI scans also 
provide information as to the need to perform any 
mitigation techniques by changing the volume of the 
bladder, or filling the rectum with ultrasound gel using 
Sengstaken-Blakemore tube. 
TREATMENT PLANNING 
When the position of the patient has been finalised 
and the patient is comfortable, there follows the 
acquisition of high-resolution T2-weighted MR images 
of the pelvis in the three orthogonal planes i.e. sagittal, 
axial and coronal. These images are used to define the 
location of the fibroid, the volume to be ablated, the 
proximity of the sacrum and lumbo-sacral spine as well 
as to determine the presence of any bowel lying anterior 
to the fibroid which may lie in the beam path. The 
authors have found that using a fat-suppressed T2-
weighted imaging sequence assists in defining the 
intestine much easier (Figure 7).  
If the fibroid lies too close to the sacral area, then 
ultrasound gel (approx 250cc) can be inserted rectally to 
displace the fibroids away form the area. A safe distance 
of 4 cm is necessary. If bowel has migrated anteriorly to 
the fibroid, then saline can be infused into the bladder. 
This may need to be followed with insertion of rectal gel. 
The skin-gel pad interface needs to be defined. This is 
followed by marking out the critical structures i.e. the 
pubic bone, bowel and far field bone (the spine and 
sacrum) using specific low-energy density region 
markers.  
The region of treatment (ROT) is then defined on 
the targeted fibroid. This ROT is placed on the coronal 
images. The ROT is drawn such that a margin of at least 
1 cm is kept from the serosal surfaces to minimise the 
risk of ablating the serosa which causes severe pain. 
There is no limit to the percentage of fibroid volume that 
can be treated though generally a 60-70% of ablation is 
necessary for good outcomes [13]. The operator then 
chooses the treatment plan depending on the size and 
type of fibroid being treated. For “white fibroids”, a 
nominal high-density plan should be selected, otherwise 
a medium-density plan would be suitable. The length of 
the sonications can then be selected and may vary from 
10 mm to 45 mm. Based on the treatment plan chosen, 
the FUS system automatically displays a series of 
sonications to cover the region of treatment. Each spot is 
cylindrically shaped, 25 to 45 mm in length and 5 mm in 
diameter for a nominal fibroid. 
The sonication beam path is carefully checked to 
ensure that it does not pass through any structures that 
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(a) (b) (c) 
Figure 5  (a) Type A multiple area of focal adenomyosis (round) (blue dotted ring) seen in both anterior and 
posterior walls on the sagittal T2-WI; (b) and (c) post-contrast T1-WI following MRgFUS showing 
good response. 
 
     
(a) (b)  (c) 
Figure 6  (a) Type B (serrated) area of focal adenomyosis seen in the posterior wall on the sagittal T2-WI; (b) 
axial and (c) sagittal post-contrast T1-WI following MRgFUS showing poor treatment (arrows) 
response with serrated margins. 
 
   
(a) (b) 
Figure 7  Defining the bowel on treatment planning (a) T2 WI in sagittal plane followed by T2WI with fat 
saturation shows the bowel (arrow) clearly against the suppressed intra-peritoneal fat. 
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should be avoided – such as the small bowel that can fall 
in front of the uterus. 
Generally, treating and ablating an 8 cm fibroid 
takes approximately 3 h of sonications (that is excluding 
the patient preparation and planning), depending on 
energy absorption and location of the fibroid. Fibroids 
that are larger than 10 cm are less suitable for the 
treatment because of the long treatment time. However 
two options are available: 
1.  Treating the fibroid over two sessions 
performed preferably with the fibroid volume 
being split into a superior and an inferior region 
for each of the treatment. This is to avoid the 
ultrasound beam in the second treatment from 
passing through already treated regions if an 
anterior-posterior division was made.  
2.  Or as mentioned previously, use pre-treatment 
with GnRH agonist prior to MRgFUS to shrink 
the fibroid and improve treatment outcomes 
[15].  
TREATMENT 
Before treatment, the patient is asked to press the 
emergency button. One or more low-energy 'verification' 
sonications are then delivered to calibrate the location of 
the actual target spot against the planned target location 
(Figure 8). This is monitored on the temperature maps, 
which are displayed real time during the course of the 
sonications. These sonications also allow a titration of 
the energy to the patient progressively rather than being 
treated with a large dose in a single step.  
The system will display the total number of 
sonication spots on the defined ROT. These spots are 
green, yellow or red (just like traffic lights) to indicate 
the safety of each sonication spot. The green spots can be 
safely treated while the yellow spots generally indicate 
that the energy density reaching the marked out areas of 
the sacrum has exceeded a system-defined lower safety 
limit. One can still treat these yellow spots but should try 
to modify the sonication parameters appropriately and 
ensure post sonication that the patients do not have 
discomfort in their back or radiation down their lower 
limbs. However, when the spots turn red, the system will 
not allow you to sonicate. This is generally due to areas 
of bowel, which lie within the beam pass zone and pass 
through the pubic bone or the energy density in the 
posterior pelvis reaching a system-defined upper margin. 
The beam must be angled to avoid the bowel, parameters 
changed or the spot moved.  
Each sonication duration varies from 20 to 
30 seconds. This is followed by cooling periods of 24 to 
90 seconds. The cooling periods allow time for the skin 
to cool down; otherwise patients may suffer skin burns. 
Thermal feedback is generated by real-time PRF while 
magnitude images highlight the temperature changes and 
the anatomy in the targeted area. A temperature graph 
shows the temperature change on the temperature maps 
(Figure 9). Once the targeted tissue reaches the desired 
temperature leading to thermal necrosis [27] system 
automatically highlights the treated areas in blue 
(Figure 10). The sonications can be monitored in axial, 
coronal or the sagittal plane.  
For the patient’s safety, a cooling period between 
each sonication is programmed into the treatment plan, to 
allow cooling of tissue outside and anterior to the 
treatment zone. This cooling duration varies depending 
on the output energy and how close the next sonication is 
to the area just treated, but is generally between 40 and 
70 seconds. Using an interleaved mode in large fibroids 
shortens the cooling time and hastens the treatment time 
where subsequent sonications anterior pass zones do not 
intersect. 
Sonication parameters can be changed, if necessary, 
including energy, duration, spot size and frequency 
depending on the response seen in the previous treatment 
or due to pain or discomfort (Figure 11). 
During each sonication, magnitude images, which 
display the position of the uterus relative to the electronic 
3D special markers (fudicials) placed at the beginning of 
treatment on the T2 images, are obtained, and allows for 
determination of any movement of the uterus and patient. 
After all the sonications have been completed and 
the dose volume is determined to be adequate for fibroid 
destruction, the treatment has ended. Post-treatment fat-
saturated T2WI are obtained to assess the skin and 
abdominal muscles for the presence of any hyperemia 
(Figure 12).  
DWI changes, which include changes in both T2 
and ADC, may be useful in many cases to delineate the 
treated region resulting from MRgFUS. However, 
definite DWI changes are not always observed, and in 
some large treatments, the area of the non-perfused 
region may be under estimated [28]. Despite these 
limitations, these same sequences may be performed 
anytime during the treatment to assess damage or extent 
of ablation. The authors currently use axial DWI images 
using B values of 600 to assess the size of ablation 
(Figure 13). 
A series of contrast-enhanced T1-weighted images 
are acquired to determine the treatment outcome, which 
shows the treated fibroid as non-enhancing (Figure 14). 
In the authors' practice, gadolinium contrast is not given 
intra-procedurally because there is a possibility that the 
gadolinium chelate will dissociate and the free 
gadolinium may become fixed in the tissues. The long-
term effects of such exposure are not known. Therefore 
in the authors' centre, once the intravenous gadolinium 
has been given, the treatment has to be terminated.  
Immediately following treatment, the patient’s skin 
is checked for the presence of any burns. In one study, 
approximately 11% of patients developed some 
inflammatory changes in the near field but these changes 
cause minimal if any post-treatment discomfort to the 
patients [29]. It is vital that the near field structures are 
monitored for heating on thermal images acquired during 
sonications. Occasional in-treatment acquisition of T2-
weighted fat saturation images are helpful in detecting 
these changes early, especially if there is an awareness of 
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Figure 8  The verification sonication (blue ring) on the coronal image. The red crosses “X” are the fudicial 
markers to identify the uterus, pelvic bones, and bladder to ascertain if the patient has moved during the 
treatment. 
 
 
Figure 9  The post sonication temperature display of the tissue temperature in the fibroid after the treatment has 
been delivered. 
 
   
(a) (b) 
Figure 10 (a) The areas in dark blue are previous treatment areas that have achieved the desired thermal dose. The 
rectangular box (lighter blue) shows the current sonications application while the green area shows the 
current sonications dose map. (b) The inverted light blue cones show the beam path which can be 
angulated to avoid critical structures. The rectangular box (yellow) shows the current sonication has 
exceeded the recommended dose but can still be delivered. The areas of red are phase shift artefacts. 
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Figure 11 The system allows changes to the energy, frequency, spot parameters depending on the patient comfort 
and the response of the fibroids to the sonications. The system also displays the spot length, diameter of 
the sonication spot along with the angulation of the beam (roll and pitch). 
 
 
 
 
 
* *
 
Figure 12 Post-contrast T1WI in sagittal plane showing enhancement of the subcutaneous tissue (arrow) and 
ablated region of fibroid (asterisk). 
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(a) (b) 
Figure 13 (a) Coronal DWI images compared to (b) post-contrast fat suppressed T1WI to assess the extent of 
ablation (arrows) at the same level. 
 
 
 
   
(a) (b) 
   
(c) 
Figure 14 T1W post contrast enhanced images showing (a) poor (b) average and (c) good ablation (arrows). 
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the location of patient discomfort associated with 
sonications. 
The authors do prescribe some post-procedure 
analgesics to take should patients experience any pain. 
Patients are provided with the contact phone number of 
the gynecologist should they need any assistance. 
Following treatment, the patient generally remains in the 
MRI suite for one hour to recover from the sedation. 
Then they are discharged and accompanied home by 
their spouse or a relative.  
MONITORING OUTCOMES 
On the day following treatment, they should be able 
to return to their normal activities with no unusual events 
and no medication. The authors subsequently plan for 
them to visit the interventional radiology clinic in 
2  weeks and see the gynecologist at the same time. 
Patients for whom treatment could not be completed 
because of the large size or number, a repeat treatment is 
planned anytime from 1 week onwards. Follow-up 
contrast-enhanced MRI is performed after 6 months to 
assess the fibroid size (Figure 15).  
Patient-reported outcomes of symptom severity and 
Health-Related Quality of Life (HRQL) are becoming 
increasingly important for evaluating treatment of uterine 
fibroids within the clinical setting. The Uterine Fibroid 
Symptom and Health Related Quality of Life 
Questionnaire (UFS-QOL) is a uterine fibroid-specific 
questionnaire developed specifically to evaluate the 
symptoms of uterine fibroids and their impact on HRQL. 
The UFS-QOL appears to be a useful evaluative tool for 
assessing symptoms and HRQL in studies among 
patients with uterine fibroids [30]. The authors screen 
their patients using these criteria to assess response.  
SUMMARY 
MR-guided focused Ultrasound provides an 
important new non-invasive and effective treatment for 
uterine fibroids. MRgFUS can be offered to the majority 
of patients suffering from symptomatic uterine fibroids 
[21]. They suggest that the use of broader inclusion 
criteria as well as the mitigation techniques makes it 
possible to offer MRgFUS to a much larger subset of 
patients than previously believed (Table 2). Recovery 
from the treatment is almost immediate and symptom 
relief is generally noticed sooner than alternative 
therapies. This is a tremendous advantage over existing 
options, which place a large burden on patients. 
Additional applications e.g. drug deliveries are under 
investigation and hold the promise of transforming the 
surgical arena to benefit millions of patients. 
Table 2  Comparison of assessment criteria used in earlier studies and the current St. Mary’s centre [19]. 
Clinical factors   Prior study   St. Mary’s study  
Insufficient symptoms of fibroids   SSS < 21 Excluded   Not relevant  
Age < 40 or >60 years  Excluded  Not relevant  
Desires pregnancy   Excluded   Not relevant  
Menopausal   Excluded   Not relevant  
Obesity >250Ibs   Excluded   Excluded  
Prior UFE   Excluded   Not relevant  
IUD, MR imaging incompatibility   Excluded  Excluded  
Technical factors  Prior study   St. Mary’s study  
Too much fibroid volume >900 cc   Excluded   Not relevant  
Bowel obstructing beam path   Excluded   Partly mitigated  
Significant adenomyosis   Excluded   Excluded  
Pedunculated fibroids   Excluded   Excluded  
Fibroids too small or no fibroids   Excluded   Excluded  
Bright T2 fibroid   Excluded   Partly mitigated  
Degenerating, necrotic, or infarcted fibroids   Excluded   Excluded  
Arterial-venous malformation, calcified fibroids, or 
conglomerate of fibroids or septated fibroids hard to 
transmit heat across 
Excluded   Excluded  
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(a) (b)  (c) 
Figure 15 Fat saturated post-contrast T1WI (a) at baseline prior to treatment (b) following completion of ablation 
with area of non perfusion seen centrally and (c) at 6 months follow-up. 
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